Kezar Life Sciences shares are trading higher after the company announced it will be acquired by Aurinia Pharmaceuticals for $6.955 in cash per share plus a contingent value right.

Benzinga Newsdesk www.benzinga.com Positive 94.5%

Neg 0% Neu 0% Pos 94.5%

Comments

No comments yet. Be the first!